Diagnostic Value of CT, Conventional MRI, and Gadoxetic Acid–Enhanced MRI in Detecting Hepatocellular Carcinoma

Tại các buổi hội chẩn U gan thứ 3 mỗi tuần tại khoa Ngoại gan mật tụy, CT scan và MRI là 2 công cụ chính trong đánh giá tổn thương gan, đặc biệt khi nghi ngờ HCC. Và MRI với chất thương phản đặc hiệu gan như gadoxetic acid (Premovist) giúp khảo sát đồng thời pha mạch máu và nhu mô gan được các anh nhắc đến như “vũ khí tối thượng” trong chẩn đoán. Vậy, câu hỏi đặt ra là: “CT, MRI và MRI Premovist khác biệt thế nào về giá trị chẩn đoán đối với HCC?”

I. COMPARATIVE DIAGNOSTIC PERFORMANCE: CT, CONVENTIONAL MRI, AND PRIMOVIST MRI

1. Quantitative Diagnostic Accuracy

The diagnostic accuracy of each imaging modality for HCC in cirrhotic patients with hepatitis B has been rigorously evaluated in meta-analyses and systematic reviews. Multiphasic contrast-enhanced CT demonstrates a pooled sensitivity of 66–78% and specificity of 91–92% for HCC of any size, with sensitivity dropping to as low as 34% for lesions 1–1.9 cm in diameter. MRI with extracellular contrast agents (EC-MRI) offers higher sensitivity, ranging from 82–89%, and specificity of 92–94%. MRI with hepatobiliary-specific contrast agents (Primovist/Eovist, HBA-MRI) achieves the highest sensitivity, 85–95%, and specificity of 92–94%, particularly excelling in the detection of small or early HCC lesions. 

For lesions smaller than 2 cm, which are common in surveillance and early detection, the sensitivity of CT drops to 34–68%, while EC-MRI achieves 64–83%, and Primovist MRI reaches 67–87%. Specificity remains high for all modalities, but HBA-MRI may have slightly lower specificity for small nodules due to overlap with high-grade dysplastic nodules and some benign lesions. This trade-off between sensitivity and specificity is particularly relevant when interpreting indeterminate lesions in cirrhotic livers.

Hepatocellular Carcinoma in a 65-Year-Old Male Patient

Management of Hepatocellular Carcinoma: A Review. JAMA Surg. April 1, 2023.

2. Clinical Implications for Small Lesion Detection

The detection of small HCC lesions (<2 cm) is a critical challenge in cirrhotic patients. MRI, especially with hepatobiliary-specific contrast, is significantly more sensitive than CT for these lesions. For example, in a meta-analysis of eight prospective studies, Primovist MRI had a sensitivity of 79% for lesions <2 cm, compared to 46% for CT, with similar specificity (94% vs. 93%).^[4] The addition of the hepatobiliary phase in Primovist MRI increases the detection of hypovascular or early HCCs, which may not display classic enhancement patterns on CT or EC-MRI.^[6][12] However, the specificity for small nodules may decrease, necessitating careful clinical correlation and, in some cases, follow-up imaging or biopsy.^[13]

II. GUIDELINE-BASED INDICATIONS AND PRIORITIZATION

1. Surveillance

The American Association for the Study of Liver Diseases (AASLD) and the American College of Radiology (ACR) recommend semiannual ultrasound (US) with alpha-fetoprotein (AFP) as the standard for routine HCC surveillance in cirrhotic patients, including those with hepatitis B. Cross-sectional imaging with CT or MRI (with or without hepatobiliary contrast) is reserved for cases where ultrasound is technically inadequate, such as in patients with obesity, nodular livers, or poor acoustic windows.^[2][14] Routine use of CT or MRI for surveillance in all patients is not recommended due to cost, accessibility, and lack of evidence for improved outcomes.

2. Diagnosis

When a new liver lesion ≥1 cm is detected on surveillance US or when there is a significant rise in AFP, both the AASLD and the National Comprehensive Cancer Network (NCCN) recommend diagnostic evaluation with multiphasic contrast-enhanced CT or MRI. The diagnosis of HCC can be established noninvasively if the lesion demonstrates arterial phase hyperenhancement (APHE) and washout on portal venous or delayed phases. Both CT and MRI are considered first-line and equivalent for diagnosis, with the choice determined by local expertise, availability, and patient factors.^[2][15-16] MRI, particularly with hepatobiliary-specific contrast, is preferred for small or indeterminate lesions due to its higher sensitivity.^[4][6]

3. Staging

For staging, both multiphasic CT and contrast-enhanced MRI are recommended to assess tumor burden, vascular invasion, and extrahepatic spread. MRI may be preferred for detailed intrahepatic assessment, especially for small or satellite lesions, but both modalities are acceptable.^[2][14-15] The AASLD does not recommend routine use of PET or bone scans for staging due to low sensitivity for HCC.

4. Post-Treatment Surveillance

For post-treatment surveillance after resection, ablation, or transplantation, both multiphasic CT and MRI (with or without hepatobiliary contrast) are considered appropriate and equivalent. MRI with hepatobiliary contrast may be particularly useful for detecting small intrahepatic recurrences or satellite nodules, given its higher sensitivity in this context.^[6][14] 

III. STRENGTHS AND LIMITATIONS OF EACH MODALITY

1. CT

Multiphasic contrast-enhanced CT is widely available, rapid, and less susceptible to motion artifacts. It provides high specificity for HCC diagnosis when classic imaging features are present, but its sensitivity is lower than MRI, especially for lesions <2 cm. CT is essential for comprehensive staging, including assessment of extrahepatic disease and vascular invasion. Limitations include exposure to ionizing radiation, potential nephrotoxicity from iodinated contrast, and reduced sensitivity in fatty liver or iron overload.^{[1-2][5-6][17]}

2. Conventional MRI (EC-MRI)

EC-MRI offers superior soft tissue contrast, higher sensitivity for small HCCs, and multiparametric assessment (T1, T2, diffusion-weighted imaging). It is particularly adept at identifying the major LI-RADS features of HCC, such as APHE, non-peripheral washout, and enhancing capsule. Limitations include higher cost, longer scan times, greater susceptibility to motion artifacts, and technical complexity. MRI may be less available in some settings and is contraindicated in patients with certain implants or severe claustrophobia.^[2][5-6][8]

3. Primovist MRI (HBA-MRI)

MRI with hepatobiliary-specific contrast agents (Primovist/Eovist) provides both dynamic vascular imaging and a delayed hepatobiliary phase, increasing sensitivity for HCC, especially for small and early lesions. It is particularly valuable for detecting hypovascular or early HCCs and for characterizing indeterminate lesions. Limitations include lower specificity for small nodules, potential artifacts (e.g., transient dyspnea during arterial phase), reduced image quality in advanced cirrhosis, and the need for precise timing of image acquisition.^[6][11][13]

Đặc điểm	CT scan đa pha	MRI với chất tương phản ngoại bào	MRI Primovist (gadoxetic acid)
Cơ chế hoạt động	Thuốc cản quang iod, đánh giá động học mạch máu qua các thì (động mạch, tĩnh mạch, muộn)	Gadolinium ngoại bào, đánh giá động học mạch máu, không vào tế bào gan	Gadoxetic acid: 50% ngoại bào, 50% hấp thu vào tế bào gan (thì gan đặc hiệu)
Đặc điểm hình ảnh HCC	Tăng quang thì động mạch, rửa thuốc thì tĩnh mạch/ muộn, bờ rõ, có thể thấy xâm lấn mạch	Tương tự CT, thêm ưu thế phân giải mô mềm, đánh giá khuếch tán	Như MRI thường, cộng thêm: tổn thương HCC giảm tín hiệu thì gan đặc hiệu
Ưu điểm	Phổ biến, nhanh, đánh giá tốt tổn thương lớn, xâm lấn mạch, di căn ngoài gan	Độ phân giải mô mềm cao, nhạy hơn CT với tổn thương nhỏ, không tia xạ	Nhạy nhất với tổn thương nhỏ/ sớm, phát hiện tổn thương không điển hình, đánh giá tái phát sớm
Nhược điểm	Nhạy kém với tổn thương <2cm, tia xạ, độc thận do iod	Thời gian chụp dài, đắt, dễ nhiễu động, chống chỉ định với một số thiết bị	Đắt, kỹ thuật phức tạp, giảm đặc hiệu với nốt nhỏ, cần kinh nghiệm đọc phim
Chỉ định ưu tiên	Đánh giá giai đoạn, khi không có MRI, hoặc cần khảo sát ngoài gan	Phát hiện tổn thương mới, tổn thương nhỏ, tổn thương không điển hình trên CT	Phát hiện tổn thương nhỏ, tổn thương không điển hình, theo dõi sau điều trị
Liều lượng chất cản quang	1.5–2 mL/kg iod, tối đa 150 mL	0.1 mmol/kg gadolinium ngoại bào	0.025 mmol/kg gadoxetic acid, thì gan đặc hiệu sau 20 phút
Khuyến cáo của hội chuyên ngành	Được khuyến cáo tương đương MRI trong chẩn đoán và đánh giá HCC (AASLD, NCCN)	Được khuyến cáo tương đương CT, ưu tiên khi cần phát hiện tổn thương nhỏ (AASLD, NCCN)	Được chấp nhận, ưu tiên khi cần phát hiện tổn thương nhỏ hoặc không điển hình (AASLD)

IV. DIFFERENTIAL DIAGNOSIS AND IMAGING-BASED DISTINCTION

1. Differential Diagnosis in Cirrhosis and Hepatitis B

In cirrhotic patients with hepatitis B, the differential diagnosis for new liver lesions includes HCC, regenerative nodules, dysplastic nodules (low- and high-grade), cholangiocarcinoma, hemangioma, hepatic adenoma, metastatic disease, and infectious lesions such as abscesses. The risk of HCC is markedly elevated, but other entities must be considered, especially for small or atypical lesions.^[15][18-24]

2. Imaging Features Distinguishing HCC from Other Lesions

HCC is characterized by arterial phase hyperenhancement, washout in the portal venous or delayed phase, and a capsule appearance on CT or MRI. On Primovist MRI, HCC typically appears hypointense in the hepatobiliary phase due to loss of normal hepatocyte function. Regenerative nodules are usually iso- or hypointense without enhancement, while high-grade dysplastic nodules may show mild enhancement and can be hypointense on hepatobiliary phase if they have lost some hepatocellular function. Cholangiocarcinoma presents as a mass-forming lesion with delayed enhancement and is also hypointense on hepatobiliary phase. Hemangiomas show peripheral nodular enhancement with progressive centripetal fill-in and are iso- or hyperintense on hepatobiliary phase. Metastases and abscesses are typically hypointense on hepatobiliary phase and have variable enhancement patterns.^[18-24]

The following table summarizes the key imaging features of common liver lesions in cirrhosis and hepatitis B, which is essential for accurate differential diagnosis and appropriate management:

Lesion Type	Typical Imaging Features (CT/MRI)	Primovist MRI Features	Clinical Relevance in Cirrhosis/HBV
HCC	Arterial enhancement, washout, capsule	Hypointense in hepatobiliary phase	Most common malignancy; urgent dx
Regenerative nodule	Iso/hypointense, no enhancement	Iso/hyperintense	Benign, common in cirrhosis
Dysplastic nodule	Variable, may show mild enhancement	Iso/hyperintense (low-grade); hypointense (high-grade)	Premalignant, surveillance needed
Cholangiocarcinoma	Mass-forming, delayed enhancement	Hypointense	Less common, consider if atypical
Hemangioma	Peripheral nodular enhancement, fill-in	Iso/hyperintense	Benign, may mimic malignancy
Hepatic adenoma	Hypervascular, well-defined	Variable, often iso/hyperintense	Rare in cirrhosis, risk of bleed
Metastasis	Variable, often multiple, rim enhancement	Hypointense	Consider with extrahepatic cancer
Abscess/infection	Rim enhancement, central necrosis	Hypointense	Consider with fever, leukocytosis

V. PRACTICAL RECOMMENDATIONS FOR MODALITY SELECTION AND IMPLEMENTATION

1. Surveillance Strategy

For this patient with compensated cirrhosis and chronic hepatitis B, semiannual ultrasound with AFP remains the first-line surveillance strategy. If ultrasound is technically inadequate, cross-sectional imaging with either multiphasic CT or MRI (with or without hepatobiliary contrast) should be implemented. When using MRI for surveillance, a protocol including T1, T2, diffusion-weighted imaging, and hepatobiliary phase (if using Primovist) is recommended. The interval for surveillance should remain every 6 months, as per guideline recommendations.^[2][14]

2. Diagnostic Workup of New Lesions

Upon detection of a new liver lesion ≥1 cm or a significant rise in AFP, immediate diagnostic evaluation with either multiphasic contrast-enhanced CT or MRI is warranted. If MRI is available and expertise exists, it should be prioritized, especially for lesions <2 cm or when the lesion is indeterminate on CT. The MRI protocol should include dynamic phases (arterial, portal venous, delayed) and, if using Primovist, a hepatobiliary phase at 20 minutes post-injection. Lesions demonstrating APHE and washout, particularly if hypointense on hepatobiliary phase, can be diagnosed as HCC without biopsy in this clinical context.^{[2][4][6][15]}

If the lesion is indeterminate or does not meet noninvasive diagnostic criteria, repeat imaging with an alternative modality or short-interval follow-up (3–6 months) is recommended. Biopsy should be reserved for lesions that remain indeterminate after comprehensive imaging or when the diagnosis will alter management.^[2][15-16]

3. Staging and Pre-Treatment Assessment

For confirmed HCC, comprehensive staging with either multiphasic CT or MRI is required to assess tumor burden, vascular invasion, and extrahepatic spread. MRI is preferred for detailed intrahepatic assessment, especially for small or satellite lesions, but CT remains acceptable and may be necessary for evaluating extrahepatic disease or when MRI is contraindicated.^[2][14-15]

4. Post-Treatment Surveillance

After curative treatment (resection, ablation, or transplantation), surveillance for recurrence should be performed with either multiphasic CT or MRI every 3–6 months for the first 2 years, then every 6–12 months thereafter. MRI with hepatobiliary contrast is particularly advantageous for detecting small intrahepatic recurrences or satellite nodules. The imaging protocol should include dynamic phases and, if using Primovist, a hepatobiliary phase.^[6][14]

5. Special Considerations and Implementation Details

MRI with hepatobiliary-specific contrast (Primovist/Eovist) should be prioritized for patients with small or indeterminate lesions, for early detection, and for post-treatment surveillance when maximal sensitivity is required. The standard dose of gadoxetic acid (Primovist/Eovist) is 0.025 mmol/kg, administered as a rapid intravenous bolus, followed by dynamic imaging and a hepatobiliary phase at 20 minutes post-injection.^[11] For CT, a standard multiphasic protocol with arterial, portal venous, and delayed phases should be used, with iodinated contrast dosed at 1.5–2 mL/kg, not exceeding 150 mL per scan, and appropriate renal function assessment prior to administration.

When interpreting imaging, the use of standardized reporting systems such as LI-RADS is strongly recommended to improve diagnostic confidence and reproducibility. LI-RADS LR-5 lesions have a >95% probability of being HCC in at-risk populations, including those with cirrhosis and hepatitis B.^[2][26]